BR112012014624A2 - suspensão homogênea de compostos de imunopotenciação e usos dos destes - Google Patents
suspensão homogênea de compostos de imunopotenciação e usos dos destesInfo
- Publication number
- BR112012014624A2 BR112012014624A2 BR112012014624A BR112012014624A BR112012014624A2 BR 112012014624 A2 BR112012014624 A2 BR 112012014624A2 BR 112012014624 A BR112012014624 A BR 112012014624A BR 112012014624 A BR112012014624 A BR 112012014624A BR 112012014624 A2 BR112012014624 A2 BR 112012014624A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- immunopotentiation
- homogeneous suspension
- homogeneous
- suspensions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
suspensão homogênea de imunopetemciação de compostos e usos dos mesmos. a presente invenção geralmente refere-se a suspensões homogêneas de potenciadores de moléculas pequenas imunes (smips) que são capazes de estimular ou modular a resposta imune em um sujeito em necessidade desse facto. as suspensões homogêneas podem ser usados em combinações com vários antígenos ou adjuvantes para vacinas terapêuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28675409P | 2009-12-15 | 2009-12-15 | |
PCT/US2010/060621 WO2011084549A1 (en) | 2009-12-15 | 2010-12-15 | Homogeneous suspension of immunopotentiating compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012014624A2 true BR112012014624A2 (pt) | 2016-03-01 |
BR112012014624A8 BR112012014624A8 (pt) | 2017-12-26 |
Family
ID=43920779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012014624A BR112012014624A8 (pt) | 2009-12-15 | 2010-12-15 | suspensão homogênea de compostos de imunopotenciação e usos dos destes |
Country Status (11)
Country | Link |
---|---|
US (2) | US9408907B2 (pt) |
EP (1) | EP2512478B1 (pt) |
JP (2) | JP5814933B2 (pt) |
CN (1) | CN102762206A (pt) |
AU (1) | AU2010339921B2 (pt) |
BR (1) | BR112012014624A8 (pt) |
CA (1) | CA2784580A1 (pt) |
ES (1) | ES2631977T3 (pt) |
MX (1) | MX339146B (pt) |
SG (2) | SG181712A1 (pt) |
WO (1) | WO2011084549A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2502631A1 (en) * | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immune suppressor and its use |
CA2888721A1 (en) * | 2012-10-25 | 2014-05-01 | Glaxosmithkline Biologicals Sa | Nicotinamide as adjuvant |
CN103784966B (zh) * | 2014-01-23 | 2016-03-23 | 广东省农业科学院动物卫生研究所 | 羧甲基纤维素钠在鸡球虫活卵囊疫苗中的应用 |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
CN108472344A (zh) * | 2015-11-03 | 2018-08-31 | 阿费里斯股份公司 | 用于针对人患者中的自身抗原的疫苗接种方法 |
CN106045902A (zh) * | 2016-06-30 | 2016-10-26 | 苏州健雄职业技术学院 | 一种3‑溴‑6‑甲基‑2‑吡啶甲醛的制备方法 |
GB202215414D0 (en) * | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
US4726912A (en) * | 1986-08-27 | 1988-02-23 | Phillips Petroleum Company | Stable suspensions of carboxymethyl cellulose and their preparation |
US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
JP2000511769A (ja) | 1996-04-02 | 2000-09-12 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
EP0914330A4 (en) | 1996-05-14 | 2002-01-09 | Smithkline Beecham Corp | NEW TYPE COMPOUNDS |
ES2277362T5 (es) | 1996-10-31 | 2014-12-18 | Human Genome Sciences, Inc. | Antígenos y vacunas de streptococcus pneumoniae |
GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
ES2301181T3 (es) | 1997-08-21 | 2008-06-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas. |
BR9813930A (pt) | 1997-11-06 | 2006-12-19 | Chiron Spa | antìgeno neisserial |
WO1999027109A2 (en) | 1997-11-26 | 1999-06-03 | Inhibitex, Inc. | EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS) |
DK1047784T4 (en) | 1998-01-14 | 2015-06-15 | Novartis Vaccines & Diagnostic | NEISSERA meningitidis ANTIGENS |
JP2002516251A (ja) | 1998-04-23 | 2002-06-04 | ユーエイビー リサーチ ファンデーション | 肺炎球菌表面プロテインC(PspC)のエピトープ領域およびその菌株選択、ならびにそのための使用法 |
EP2261345A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
DE69935986D1 (de) | 1998-07-27 | 2007-06-14 | Sanofi Pasteur Ltd | Streptococcus pneumoniae proteine und nukleinsäuren |
WO2000006738A2 (en) | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE) |
CN1314450C (zh) | 1998-08-31 | 2007-05-09 | 英希比泰克斯公司 | 多组分疫苗 |
CN1283798C (zh) | 1998-08-31 | 2006-11-08 | 都柏林伊丽莎白女皇神学院 | 凝固酶阴性葡萄球菌的多肽及多核苷酸 |
EP1144998A3 (en) | 1998-10-09 | 2002-08-07 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
US6582706B1 (en) | 1998-12-21 | 2003-06-24 | Medimmune, Inc. | Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS |
EP1165795A2 (en) | 1999-03-26 | 2002-01-02 | Provalis UK Limited | Streptococcus pneumoniae antigens |
ATE325620T1 (de) | 1999-06-10 | 2006-06-15 | Medimmune Inc | Streptococcus pneumoniae proteine und impfstoffe |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
PT1248647E (pt) | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
AU3948801A (en) | 2000-02-28 | 2001-09-12 | Chiron Spa | Heterologous expression of neisserial proteins |
EP1268774A2 (en) | 2000-03-21 | 2003-01-02 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
CA2407455A1 (en) | 2000-04-27 | 2001-11-01 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
US6495079B1 (en) | 2000-06-28 | 2002-12-17 | Prisma Fibers, Inc. | Process to prepare polymeric fibers with improved color and appearance |
WO2002002606A2 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
AU2001287645A1 (en) | 2000-07-20 | 2002-02-05 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumiae |
EP1322328B1 (en) | 2000-07-27 | 2014-08-20 | Children's Hospital & Research Center at Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
AU2001295795A1 (en) | 2000-10-26 | 2002-05-06 | Imperial College Innovations Ltd. | Streptococcal genes |
EP2284181A1 (en) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A and B |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
AU2002306849A1 (en) | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
CA2447599C (en) | 2001-05-18 | 2015-04-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office | Peptide vaccines against group a streptococci |
CN100359327C (zh) | 2001-06-15 | 2008-01-02 | 英希比泰克斯公司 | 识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体 |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
EP1412379B1 (en) | 2001-08-02 | 2012-01-25 | The University Of Sheffield | Vaccine |
NZ533428A (en) | 2001-12-12 | 2008-03-28 | Chiron Srl | Immunisation against chlamydia trachomatis |
GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
EP2275128B1 (en) | 2002-04-02 | 2013-10-16 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
DK1511768T3 (da) | 2002-06-11 | 2007-08-20 | Glaxosmithkline Biolog Sa | Immunogene sammensætninger |
GB0213622D0 (en) | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
CA2493124C (en) | 2002-08-02 | 2014-04-29 | Glaxosmithkline Biologicals S.A. | Vaccine |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
CA2498847C (en) | 2002-09-13 | 2014-10-28 | Chiron Corporation | Group b streptococcus vaccine |
DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
AU2003296414A1 (en) * | 2002-12-12 | 2004-07-09 | Pharmacia Corporation | Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
EP1618127B1 (en) | 2003-04-10 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic composition comprising a spike protein of the SARS coronavirus |
EP2298934A1 (en) | 2003-04-15 | 2011-03-23 | Intercell AG | S. pneumoniae antigens |
US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
CA2532369C (en) | 2003-07-31 | 2016-07-26 | Chiron Corporation | Immunogenic compositions for streptococcus pyogenes |
EP1725575B1 (en) | 2004-02-18 | 2012-11-28 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
BRPI0515520A (pt) | 2004-09-22 | 2008-07-29 | Glaxosmithkline Biolog Sa | composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica |
RU2432962C2 (ru) | 2005-01-27 | 2011-11-10 | Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд | Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis |
CN101389768B (zh) | 2005-12-27 | 2015-11-25 | 奥比科技有限责任公司 | 作为疾病的生物标志的生脂腺病毒 |
US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
CA2642721A1 (en) | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
AR060187A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
EA015833B1 (ru) | 2006-03-30 | 2011-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция |
AU2009222105B2 (en) | 2008-03-03 | 2012-05-17 | Novartis Ag | Compounds and compositions as TLR activity modulators |
CN101422437A (zh) * | 2008-11-14 | 2009-05-06 | 李铁军 | 一种依托泊苷干混悬剂及其制备方法 |
CN102762226A (zh) * | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
-
2010
- 2010-12-15 MX MX2012006987A patent/MX339146B/es active IP Right Grant
- 2010-12-15 ES ES10799189.5T patent/ES2631977T3/es active Active
- 2010-12-15 AU AU2010339921A patent/AU2010339921B2/en active Active
- 2010-12-15 SG SG2012044012A patent/SG181712A1/en unknown
- 2010-12-15 BR BR112012014624A patent/BR112012014624A8/pt not_active Application Discontinuation
- 2010-12-15 WO PCT/US2010/060621 patent/WO2011084549A1/en active Application Filing
- 2010-12-15 CN CN2010800637486A patent/CN102762206A/zh active Pending
- 2010-12-15 EP EP10799189.5A patent/EP2512478B1/en active Active
- 2010-12-15 SG SG10201501980SA patent/SG10201501980SA/en unknown
- 2010-12-15 US US13/516,227 patent/US9408907B2/en active Active
- 2010-12-15 CA CA2784580A patent/CA2784580A1/en not_active Abandoned
- 2010-12-15 JP JP2012544804A patent/JP5814933B2/ja active Active
-
2015
- 2015-04-28 JP JP2015091257A patent/JP2015134828A/ja not_active Withdrawn
-
2016
- 2016-07-05 US US15/201,651 patent/US10046048B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG181712A1 (en) | 2012-07-30 |
JP5814933B2 (ja) | 2015-11-17 |
BR112012014624A8 (pt) | 2017-12-26 |
JP2013514382A (ja) | 2013-04-25 |
US20130101629A1 (en) | 2013-04-25 |
US20160375132A1 (en) | 2016-12-29 |
CA2784580A1 (en) | 2011-07-14 |
SG10201501980SA (en) | 2015-05-28 |
ES2631977T3 (es) | 2017-09-07 |
US10046048B2 (en) | 2018-08-14 |
MX339146B (es) | 2016-05-13 |
EP2512478A1 (en) | 2012-10-24 |
JP2015134828A (ja) | 2015-07-27 |
CN102762206A (zh) | 2012-10-31 |
US9408907B2 (en) | 2016-08-09 |
AU2010339921A1 (en) | 2012-07-12 |
EP2512478B1 (en) | 2017-04-19 |
MX2012006987A (es) | 2012-07-17 |
WO2011084549A1 (en) | 2011-07-14 |
AU2010339921B2 (en) | 2016-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012014624A2 (pt) | suspensão homogênea de compostos de imunopotenciação e usos dos destes | |
CY1123404T1 (el) | Αντι-girt αντισωματα | |
BR112014007852A2 (pt) | nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos | |
BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
EA200901270A1 (ru) | Стимуляция иммунной реакции катионными липидами | |
NL300914I2 (nl) | Atezolizumab | |
BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
AR091649A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos | |
BR112014023898A2 (pt) | moléculas de ácido nucleico artificiais compreendendo 5''utr top | |
BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
BR112012005225B8 (pt) | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
BRPI0712816B8 (pt) | compostos de pirrolpirimidina e seus usos | |
BR112014006897A2 (pt) | sistema de cabeça de fraturamento ajustável e câmara tubular | |
BRPI0815008B8 (pt) | vacinas multiméricas com múltiplos epítopos contra influenza | |
BR112018000632A2 (pt) | moléculas de anticorpo que ligam a cd79 | |
BR112015007616A2 (pt) | inibidores de mek no tratamento de doenças por vírus | |
BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |